HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC : A Single-Centre Experience

Abstract EN

Background.

HPV is a positive prognostic factor in HNSCC.

We studied the prevalence and prognostic impact of HPV on survival parameters and treatment toxicity in patients with locally advanced HNSCC treated with concomitant chemoradiation therapy.

Methods.

Data on efficacy and toxicity were available for 560 patients.

HPV was detected by PCR.

Analysis was performed using Kaplan-Meier survival curves, Fisher’s test for categorical data, and log-rank statistics for failure times.

Results.

Median follow-up was 4.7 years.

DNA extraction was successful in 255 cases.

HPV prevalence was 68.6%, and 53.3% for HPV 16.

For HPV+ and HPV−, median LRC was 8.9 and 2.2 years (P=0.0002), median DFS was 8.9 and 2.1 years (P=0.0014), and median OS was 8.9 and 3.1 years (P=0.0002).

Survival was different based on HPV genotype, stage, treatment period, and chemotherapy regimen.

COX adjusted analysis for T, N, age, and treatment remained significant (P=0.004).

Conclusions.

Oropharyngeal cancer is increasingly linked to HPV.

This study confirms that HPV status is associated with improved prognosis among H&N cancer patients receiving CRT and should be a stratification factor for clinical trials including H&N cases.

Toxicity of CRT is not modified for the HPV population.